BOSTON, MA--(Marketwire - January 28, 2013) - Harbinger Research is pleased to announce the issuance of a Special Situations report pertaining to Viratech Corporation, (PINKSHEETS: VIRA). http://www.harbingerresearch.com/clients/vira
Senior Managing Director, Brian R. Connell, CFA, states that "Overall, we view Viratech one of the most exciting companies, business models, and value propositions we have ever seen. If ultimately successful, Viratech will make the world a better place, as well as significantly enriching all of its stakeholders on a financial basis."
About Viratech Corp: Viratech Corp., an open source biotech research and development network, engages in developing cancer detection and treatment protocols in the United States. The company holds licenses to market cancer diagnostic and treatment protocols, including the unified cancer theory, the stage zero cancer protocol, and an early detection diagnostic system. It also operates a social networking Website focused on cancer research.
The Company's healthcare-focused social networking platform is complete and the Company is now in the process of launching it in multiple related verticals. The Company is based in Stockton, CA, and trades on the OTC Market under the symbol VIRA.
About Harbinger Research: Harbinger Research is a leading equity research firm that specializes in presenting highly promising opportunities to small-cap and micro-cap investors. Employing a team of CFA Charterholders and industry expert analysts, Harbinger Research is based in Boston, MA. To learn more, visit us at: www.harbingerresearch.com.